Announcement PDF Elixinol Wellness Limited Appendix 4D Half-year report 1. Company details Name of entity: Elixinol Wellness Limited ABN: 34 621 479 794 Reporting period: For the half-year ended 30 June 2026 Previous period: For the half-year ended 30 June 2025 2. Results for announcement to the market The Directors present this Appendix 4D on the consolidated entity (referred to as the 'Group') consisting of Elixinol Wellness Limited (referred to as the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 30 June 2026. $'000 Revenues from ordinary activities up 2.2% to 7,813 Loss from ordinary activities after tax attributable to the owners of Elixinol Wellness Limited down 65.4% to (1,071) Loss for the half-year attributable to the owners of Elixinol Wellness Limited down 65.4% to (1,071) 30 Jun 2026 30 Jun 2025 Cents Cents Basic loss per share (0.26) (1.39) Diluted loss per share (0.26) (1.39) Dividends There were no dividends paid, recommended or declared during the current financial period. Comments The loss for the Group after providing for income tax amounted to $1,071,000 (30 June 2025: $3,093,000). 3. Net tangible assets Reporting period Previous period Cents Cents Net tangible assets per ordinary security (0.54) (1.12) Calculated as follows: Group 30 Jun 2026 30 Jun 2025 $'000 $'000 Net assets 6,364 6,965 Less: Right-of-use assets (256) (216) Less: Intangibles (4,845) (5,950) Less: Deferred tax assets (3,794) (3,591) Add: Lease liabilities 278 220 Net tangible assets (2,253) (2,572) Total shares issued (no.) 413,987,731 230,191,421 Elixinol Wellness Limited Appendix 4D Half-year report 4. Control gained over entities Not applicable. 5. Loss of control over entities Not applicable. 6. Dividends Current period There were no dividends paid, recommended or declared during the current financial period. Previous period There were no dividends paid, recommended or declared during the previous financial period. 7. Dividend reinvestment plans Not applicable. 8. Details of associates and joint venture entities Not applicable. 9. Foreign entities Details of origin of accounting standards used in compiling the report: Not applicable. 10. Audit qualification or review Details of audit/review dispute or qualification (if any): The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report. The review report contains a paragraph addressing material uncertainty related to going concern. 11. Attachments Details of attachments (if any): The Interim Report of Elixinol Wellness Limited for the half-year ended 30 June 2026 is attached. Elixinol Wellness Limited Appendix 4D Half-year report 12. Signed Authorised for release by the Board of Directors Signed ___________________________ Date: 31 August 2026 Gavin Evans Independent Non-Executive Director and Chair Elixinol Wellness Limited ABN 34 621 479 794 Interim Report - 30 June 2026 Elixinol Wellness Limited Contents 30 June 2026 1 Directors' report 2 Auditor's independence declaration 5 Consolidated statement of profit or loss and other comprehensive income 6 Consolidated statement of financial position 8 Consolidated statement of changes in equity 9 Consolidated statement of cash flows 10 Notes to the consolidated financial statements 11 Note 1. General information 11 Note 2. Material accounting policy information 11 Note 3. Critical accounting judgements, estimates and assumptions 12 Note 4. Operating segments 12 Note 5. Revenue 15 Note 6. Other income 16 Note 7. Discontinued operations 16 Note 8. Cash and cash equivalents 17 Note 9. Assets of disposal groups classified as held for sale 17 Note 10. Intangibles 17 Note 11. Borrowings 18 Note 12. Liabilities directly associated with assets classified as held for sale 19 Note 13. Issued capital 19 Note 14. Fair value measurement 20 Note 15. Contingent liabilities 21 Note 16. Earnings per share 21 Note 17. Share-based payments 22 Note 18. Events after the reporting period 23 Directors' declaration 24 Independent auditor's review report to the members of Elixinol Wellness Limited 25 Corporate directory 27 Elixinol Wellness Limited Directors' report 30 June 2026 2 The Directors of Elixinol Wellness Limited ('Elixinol Wellness' or the 'Company') present this report, together with the financial statements of the Company and its controlled entities ('Consolidated Entity' or 'Group') for the half-year ended 30 June 2026 ('H1 FY26'). Directors The Directors of the Company in office during the financial half-year and up to the date of this report are as follows: Gavin Evans Independent Non-Executive Chair Pauline Gately Independent Non-Executive Director Natalie Butler Executive Director and Chief Executive Officer The Directors were in office for the entire period unless otherwise stated. Principal activities The principal activities of the Company during the half-year comprised the development, sourcing, manufacture and supply of a range of complementary products for health-conscious consumers across three verticals: human nutrition, human wellness and superfood ingredients. The principal activities of the Group are: Australia Elixinol's Australian operations encompass a vertically integrated business that produces, manufactures, and distributes a range of highly complementary products for health-conscious consumers across three verticals – human nutrition, human wellness and superfood ingredients. These products are sold under a portfolio of brands led by The Healthy Chef and Hemp Foods Australia — the Group's two largest revenue contributors in H1 FY26. Elixinol Americas Established in 2014, Elixinol Americas is based in the United States and specialises in marketing and distributing products made from premium quality, predominantly 'whole plant' full spectrum CBD. During H1 FY26, the Company operated exclusively as an e- commerce business. Operating and financial review Revenue performance and operating expenses trend Revenue from continuing operations increased 5.8% to $7,197,000 (H1 FY25: $6,801,000), driven by strong performances from the Group's key brands. The Healthy Chef delivered revenue growth of 22%, supported by its retail expansion into Priceline Pharmacy, while Hemp Foods Australia grew revenue by +14%, with gross margin improving to 48%. The Group’s bulk hemp business, operating under the Australian Primary Hemp brand, also grew 16% compared with H1 FY25, driven by growth in hemp grocery contracts that remain in place into 2027. This brand-led growth, combined with an improved product mix, lifted Group gross margin to 43% (H1 FY25: 33%). Operating expenses reduced by 25% to $3,325,000 (H1 FY25: $4,403,000), reflecting disciplined cost management and a streamlined cost base following the Group's operational rationalisation. Statutory loss The loss for the Group after providing for income tax amounted to $1,071,000 (30 June 2025: $3,093,000), comprising a loss from continuing operations of $973,000 (H1 FY25: $2,941,000 loss) and a $98,000 loss (H1 FY25: $152,000 loss) from the discontinued US business. Underlying earnings (Adjusted EBITDA) The Group’s earnings before interest, tax, depreciation and amortisation ('EBITDA') including share of associates’ net loss and excluding impairments and share-based payments for the period ended 30 June 2026 was an Adjusted EBITDA loss of $134,000 (30 June 2025: Adjusted EBITDA loss of $2,094,000) reflecting stronger revenue, higher gross margins and the reduction in the Group's operating cost base. Elixinol Wellness Limited Directors' report 30 June 2026 3 Reconciliation of Adjusted EBITDA from continuing operations to statutory loss Group 30 Jun 2026 30 Jun 2025 $'000 $'000 Loss after income tax (973) (2,941) Add back/(deduct): Finance costs 223 279 Interest income (4) (4) Depreciation and amortisation 374 511 EBITDA (380) (2,155) Add back/(deduct): Impairment and write-off of other assets 123 262 Share-based payments 20 (101) Non-operating transactions* 103 (100) Adjusted EBITDA (134) (2,094) * Non-operating transactions comprise non-recurring restructuring, business integration and other one-time expenses that are not considered reflective of the underlying operating performance of the business. EBITDA and Adjusted EBITDA are financial measures which are not prescribed by Australian Accounting Standards ('AAS') and represent the statutory result under AAS, adjusted for certain items. The Directors consider EBITDA and Adjusted EBITDA to reflect the core earnings of the Group. Operating cash flow and balance sheet position Net operating cash outflow for H1 FY26 was $712,000, compared with $1,383,000 in H1 FY25. The improvement reflects the Group's higher gross margin and reduced cost base, with payments to suppliers and employees falling to $8,042,000 (H1 FY25: $9,631,000) and interest and other finance costs paid reducing to $122,000 (H1 FY25: $207,000), notwithstanding the absence of the $481,000 insurance recovery received in the prior corresponding period. Impairment charges Impairment charges were $123,000 in H1 FY26, compared with impairment and other asset write-off charges of $288,000 in H1 FY25. The H1 FY26 charge relates entirely to the intangible assets of the Ananda Brands cash-generating unit and comprises $41,000 against goodwill, $43,000 against the brand name and $39,000 against the patent. Significant changes in the state of affairs Change in share registry On 30 March 2026, the Company announced it changed its share registry to Boardroom Pty Limited from Automic Pty Ltd. The change became effective on 7 April 2026. Change in Company Secretary On 14 April 2026, the Company appointed Ms Mariia Skorikova and Mr Tony Di Pietro as joint Company Secretaries, replacing Ms Melanie Leydin who resigned on this date. Small parcel sale facility On 20 April 2026, the Company established a Small Parcel Sale Facility ('SPSF') for shareholders holding less than a marketable parcel of ordinary shares, being a holding valued at less than $500 based on the ASX closing share price. The facility enables eligible shareholders to sell their shares without incurring brokerage or other transaction costs, which will be borne by the Company (excluding any tax consequences arising from the sale). The SPSF is expected to reduce the administrative costs associated with maintaining a large number of small shareholdings. Based on the closing share price on 17 April 2026, the aggregate value of shares eligible under the facility was estimated at approximately $177,802. Elixinol Wellness Limited Directors' report 30 June 2026 4 On 18 June 2026, the Company announced the completion of the SPSF with 7,387 shareholders holding an aggregate of 18,788,535 shares selling with a sale price of $0.006 per share generating sale proceeds of $112,731. Settlement occurred on 26 June 2026. There were no other significant changes in the state of affairs of the Group during the financial half-year. Matters subsequent to the end of the financial half-year Subsequent to 30 June 2026, the Company received a letter of offer to divest the assets of its US business. The parties have progressed negotiations towards the execution of definitive transaction documentation. The proposed transaction is consistent with the Board’s commitment to the divestment of the US business and the Group’s strategic focus on its Australian operations. The US business has been classified as a discontinued operation and the related assets have been classified as held for sale in these financial statements in accordance with AASB 5 'Non-current Assets Held for Sale and Discontinued Operations'. Completion of the transaction remains subject to the execution of definitive agreements and the satisfaction of customary conditions precedent. The transaction is expected to generate cash proceeds for the Group and, upon completion, strengthen the Group’s liquidity position. Following the Annual General Meeting (AGM) held on 27 May 2026, at which shareholders approved a resolution to undertake a capital raising, the Group has continued to assess its funding requirements and the appropriate structure and timing of any capital raising. No equity capital raising has been implemented as at the date of this report. The Group has closed a Convertible Note offer, as approved at the AGM, to provide additional working capital and support the Group’s liquidity requirements. As at the date of this report, subscriptions totalling $1,055,000 have been received. The Directors continue to closely monitor the Group’s liquidity position and financing requirements and are progressing funding initiatives to support the Group’s ongoing working capital requirements. Other than the matters described above, there have been no other matters or circumstances that have arisen since 30 June 2026 that have significantly affected, or may significantly affect, the operations of the Group, the results of those operations, or the state of affairs of the Group in subsequent financial periods. Rounding of amounts The Company is of a kind referred to in Corporations Instrument 2026/183, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest thousand dollars, or in certain cases, the nearest dollar. Auditor's independence declaration A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this Directors' report. This report is made in accordance with a resolution of Directors, pursuant to section 306(3)(a) of the Corporations Act 2001. On behalf of the Directors ___________________________ Gavin Evans Independent Non-Executive Director and Chair 31 August 2026 THE POWER OF BEING UNDERSTOOD AUDIT | TAX | CONSULTING RSM Australia Partners is a member of the RSM network and trades as RSM. RSM is the trading name used by the members of the RSM network. Each member of the RSM network is an independent accounting and consulting firm which practices in its own right. The RSM network is not itself a separate legal entity in any jurisdiction. RSM Australia Partners ABN 36 965 185 036 Liability limited by a scheme approved under Professional Standards Legislation RSM Australia Partners Level 27, 120 Collins Street Melbourne VIC 3000 PO Box 248 Collins Street West VIC 8007 T +61 (0) 3 9286 8000 F +61 (0) 3 9286 8199 www.rsm.com.au AUDITOR’S INDEPENDENCE DECLARATION As lead auditor for the review of the financial report of Elixinol Wellness Limited and its controlled entities for the half-year ended 30 June 2026, I declare that, to the best of my knowledge and belief, there have been no contraventions of: (i) the auditor independence requirements of the Corporations Act 2001 in relation to the review; and (ii) any applicable code of professional conduct in relation to the review. RSM AUSTRALIA PARTNERS B Y CHAN Partner Melbourne, Victoria Dated: 31 August 2026 5 Elixinol Wellness Limited Consolidated statement of profit or loss and other comprehensive income For the half-year ended 30 June 2026 Group Note 30 Jun 2026 30 Jun 2025 $'000 $'000 The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes 6 Revenue from continuing operations 5 7,197 6,801 Other income 6 79 698 Interest income calculated using the effective interest method 4 4 Expenses Raw materials and consumables used and processing expenses (4,085) (4,525) Employee benefits expenses and Directors' fees (1,509) (1,988) Share-based payments (20) 101 Depreciation and amortisation expense (374) (511) Impairment of intangibles 10 (123) (25) Write off of machinery - (37) Recovery/(write off) of inventory - (213) Professional services expenses (300) (445) Sales and marketing expenses (554) (781) Administrative expenses (519) (604) Distribution costs (443) (585) Other expenses (103) (552) Finance costs (223) (279) Loss before income tax expense from continuing operations (973) (2,941) Income tax expense - - Loss after income tax expense from continuing operations (973) (2,941) Loss after income tax expense from discontinued operations 7 (98) (152) Loss after income tax expense for the half-year attributable to the owners of Elixinol Wellness Limited (1,071) (3,093) Other comprehensive income/(loss) Items that may be reclassified subsequently to profit or loss Foreign currency translation 10 (4) Other comprehensive income/(loss) for the half-year, net of tax 10 (4) Total comprehensive loss for the half-year attributable to the owners of Elixinol Wellness Limited (1,061) (3,097) Total comprehensive loss for the half-year is attributable to: Continuing operations (973) (2,941) Discontinued operations (88) (156) (1,061) (3,097) Elixinol Wellness Limited Consolidated statement of profit or loss and other comprehensive income For the half-year ended 30 June 2026 The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes 7 30 Jun 2026 Cents 30 Jun 2025 Cents Earnings per share for loss from continuing operations attributable to the owners of Elixinol Wellness Limited Basic loss per share 16 (0.24) (1.32) Diluted loss per share 16 (0.24) (1.32) Earnings per share for loss from discontinued operations attributable to the owners of Elixinol Wellness Limited Basic loss per share 16 (0.02) (0.07) Diluted loss per share 16 (0.02) (0.07) Earnings per share for loss attributable to the owners of Elixinol Wellness Limited Basic loss per share 16 (0.26) (1.39) Diluted loss per share 16 (0.26) (1.39) Group Note 30 Jun 2026 31 Dec 2025 $'000 $'000 The above consolidated statement of financial position should be read in conjunction with the accompanying notes 8 8 996 1,405 1,599 1,191 2,252 2,658 397 446 5,244 5,700 9 181 - 5,425 5,700 759 895 256 348 10 4,845 5,150 3,794 3,793 91 78 9,745 10,264 15,170 15,964 1,514 2,103 5 50 11 3,703 3,258 56 147 230 158 267 - 843 926 6,618 6,642 12 354 - 6,972 6,642 11 50 98 222 222 41 29 1,521 1,521 1,834 1,870 8,806 8,512 6,364 7,452 13 229,854 229,881 10,876 10,866 Elixinol Wellness Limited Consolidated statement of financial position As at 30 June 2026 Assets Current assets Cash and cash equivalents Trade and other receivables Inventories Prepayments and other assets Assets of disposal groups classified as held for sale Total current assets Non-current assets Property, plant and equipment Right-of-use assets Intangibles Deferred tax Prepayments and other assets Total non-current assets Total assets Liabilities Current liabilities Trade and other payables Contract liabilities Borrowings Lease liabilities Employee benefits Deferred consideration Accrued expenses Liabilities directly associated with assets classified as held for sale Total current liabilities Non-current liabilities Borrowings Lease liabilities Employee benefits Contingent consideration Total non-current liabilities Total liabilities Net assets Equity Issued capital Reserves Accumulated losses (234,366) (233,295) Total equity 6,364 7,452 Elixinol Wellness Limited Consolidated statement of changes in equity For the half-year ended 30 June 2026 The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes 9 Issued Foreign currency translation Share-based payments Accumulated capital reserve reserve losses Total equity Group $'000 $'000 $'000 $'000 $'000 Balance at 1 January 2025 228,291 9,223 387 (227,875) 10,026 Loss after income tax expense for the half-year - - - (3,093) (3,093) Other comprehensive loss for the half-year, net of tax - (4) - - (4) Total comprehensive loss for the half-year - (4) - (3,093) (3,097) Transactions with owners in their capacity as owners: Contributions of equity, net of transaction costs 137 - - - 137 Share-based payments (note 17) - - (101) - (101) Vesting of share-based payments 58 - (58) - - Transfer of historical expired rights - - (80) 80 - Balance at 30 June 2025 228,486 9,219 148 (230,888) 6,965 Issued Foreign currency translation Share-based payments Accumulated capital reserve reserve losses Total equity Group $'000 $'000 $'000 $'000 $'000 Balance at 1 January 2026 229,881 9,419 1,447 (233,295) 7,452 Loss after income tax expense for the half-year - - - (1,071) (1,071) Other comprehensive income for the half-year, net of tax - 10 - - 10 Total comprehensive income/(loss) for the half-year - 10 - (1,071) (1,061) Transactions with owners in their capacity as owners: Share issue transaction costs (note 13) (27) - - - (27) Balance at 30 June 2026 229,854 9,429 1,447 (234,366) 6,364 Elixinol Wellness Limited Consolidated statement of cash flows For the half-year ended 30 June 2026 Group 30 Jun 2026 30 Jun 2025 $'000 $'000 The above consolidated statement of cash flows should be read in conjunction with the accompanying notes 10 Cash flows from operating activities Receipts from customers (inclusive of GST) 7,428 7,947 Payments to suppliers and employees (inclusive of GST) (8,042) (9,631) Government grants 20 23 Insurance claim received - 481 Interest received 4 4 Interest and other finance costs paid (122) (207) Net cash used in operating activities (712) (1,383) Cash flows from investing activities Payments for property, plant and equipment (21) (13) Payments for intangibles - (17) Payments for security deposits (13) - Proceeds from disposal of property, plant and equipment 47 - Net cash from/(used in) investing activities 13 (30) Cash flows from financing activities Proceeds from issue of shares - 150 Share issue transaction costs - (12) Proceeds from secured loan - 1,325 Net proceeds from trade finance borrowings 397 73 Repayment of lease liabilities (91) (95) Net cash provided from financing activities 306 1,441 Net (decrease)/increase in cash and cash equivalents (393) 28 Cash and cash equivalents at the beginning of the financial half-year 1,405 1,078 Effects of exchange rate changes on cash and cash equivalents (16) (19) Cash and cash equivalents at the end of the financial half-year 996 1,087 Elixinol Wellness Limited Notes to the consolidated financial statements 30 June 2026 11 Note 1. General information The financial statements cover Elixinol Wellness Limited as a group consisting of Elixinol Wellness Limited ('Company' or 'parent entity') and the entities it controlled at the end of, or during, the period ('Group'). The financial statements are presented in Australian dollars, which is Elixinol Wellness Limited's functional and presentation currency. Elixinol Wellness Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office is: Registered office Principal place of business Suite 2 51 -53 Riversdale Road Level 11 Newtown VIC 3220 385 Bourke Street Melbourne VIC 3000 A description of the nature of the Group's operations and its principal activities are included in the Directors' report, which is not part of the financial statements. The financial statements were authorised for issue, in accordance with a resolution of Directors, on 31 August 2026. The Directors have the power to amend and reissue the financial statements. Note 2. Material accounting policy information These general purpose financial statements for the interim half-year reporting period ended 30 June 2026 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'. These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 31 December 2025 and any public announcements made by the Company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001. The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated. New or amended Accounting Standards and Interpretations adopted The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the Group during the financial half-year ended 30 June 2026 and are not expected to have a significant impact for the full financial year ending 31 December 2026. Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. Going concern The financial statements have been prepared on a going concern basis, which contemplates the continuation of normal business operations and the realisation of assets and settlement of liabilities in the normal course of business. As disclosed in the financial statements, the Group incurred a net loss before tax of $1,071,000 and had net cash outflows from operating activities of $712,000 for the half-year ended 30 June 2026. As at that date, the Group had net current liabilities of $1,547,000. These factors indicate a material uncertainty that may cast significant doubt as to whether the Group will continue as a going concern and therefore whether it will realise its assets and discharge its liabilities in the normal course of business and at the amounts stated in the half year financial report. Elixinol Wellness Limited Notes to the consolidated financial statements 30 June 2026 Note 2. Material accounting policy information (continued) 12 The Directors believe that there are reasonable grounds to believe that the Group will be able to continue as a going concern, after consideration of the following factors: ● The Group has prepared cash flow forecasts covering the period of at least 12 months from the date of approval of these financial statements, which indicate that the Group is expected to maintain sufficient liquidity to meet its obligations as they fall due. These forecasts include assumptions around a capital raising event; ● The Group is currently undertaking a capital raising and convertible note offer to provide additional working capital and support its liquidity requirements (refer note 18 Events after the reporting period). Based on the level of investor support received to date and the Group's demonstrated history of raising capital, the Directors are confident these initiatives will be completed successfully; ● The proposed divestment of the US business (refer note 7 Discontinued operations) is expected to generate cash proceeds and further strengthen the Group's liquidity upon completion; and ● The Group has demonstrated an ability to manage its operating cost base and, if required, has the capacity to further reduce discretionary expenditure and defer certain non-essential capital and operating commitments to preserve cash. Accordingly, the Directors believe it is appropriate to prepare the financial statements on a going concern basis and that it is appropriate to adopt the going concern basis in the preparation of the financial report. In the event the Group is unsuccessful at capital raising or completing the convertible note offer, and alternative funding sources were not available to be obtained, the Group would not be a going concern and therefore will not be able to realise its assets and extinguish it’s liabilities in the normal course of business, at the amounts stated in the half-year financial report. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or to the amounts and classification of liabilities, that may be necessary if the Group is unable to continue as a going concern. Note 3. Critical accounting judgements, estimates and assumptions The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities are consistent with those of the latest Annual Report. Note 4. Operating segments Identification of reportable operating segments The Group is organised into three operating segments: Australia, Americas and Rest of World. There is one single business segment, being the sale of nutraceutical and related hemp products. These operating segments are based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources. There is no aggregation of operating segments. The CODM reviews Adjusted EBITDA (earnings before interest, tax, depreciation and amortisation), adjusted for impairment. The accounting policies adopted for internal reporting to the CODM are consistent with those adopted in the financial statements. The information reported to the CODM is on a monthly basis. Types of products and